| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.15 | 0.4 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.15 | 0.4 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.038 | 0.4 |
| mRNA | Vinblastine | GDSC1000 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |